Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2026-04-03 Regulatory Filings
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to the National Stock Exchange of India. It provides clarifications regarding observations on a Corrigendum to the Notice of an Extra Ordinary General Meeting (EGM). The content mainly focuses on the shareholding pattern before and after a preferential issue of equity shares. The document is short (2622 characters) and serves as a regulatory disclosure or clarification rather than a full report or notice itself. It does not contain financial statements or detailed financial analysis, nor is it a voting result or a proxy solicitation. It is not an announcement of a report publication but a regulatory filing providing clarifications. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-04-03 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the National Stock Exchange of India Limited, informing about the closure of the trading window for insiders due to the upcoming declaration of audited financial results for the fiscal year ending 31st March 2026. It references SEBI regulations on insider trading and the company's internal code. The document does not contain any financial data, results, or detailed report content. It is a notification related to trading restrictions ahead of financial results announcement, not the financial report itself or its announcement. The document length is short (1267 characters), and it serves as an intimation or regulatory announcement rather than a report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2026-03-31 English
General Updates
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to the National Stock Exchange of India Limited. It clarifies observations related to a Corrigendum to the Notice of an Extra Ordinary General Meeting (EGM) concerning the percentage of post preferential offer capital held by various allottees. The content is focused on share allotment details and clarifications regarding a prior notice for an EGM, which is a regulatory announcement related to capital changes. The document length is short (2929 characters) and it does not contain financial statements or detailed financial analysis. It is not a full report but a regulatory disclosure clarifying shareholding percentages post a preferential offer. Therefore, it fits best under the category of Share Issue/Capital Change announcements.
2026-03-20 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to the National Stock Exchange of India Limited. It clarifies observations related to a Corrigendum to the Notice of an Extra Ordinary General Meeting (EGM) and provides detailed information on shareholding patterns before and after a preferential issue, share swap ratios, and cash considerations related to share transfers. The content focuses on shareholding changes and clarifications about an EGM notice rather than presenting a full report or financial statements. The document is not a full Annual Report, Interim Report, or Earnings Release. It is not a proxy solicitation or voting results announcement but rather a regulatory disclosure clarifying shareholding and transaction details. Given the nature of the content and the regulatory context, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-16 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document contains multiple sections, including newspaper advertisements for financial results for the quarter and nine months ended December 31, 2025, extracts of unaudited standalone and consolidated financial results, and a demand notice related to non-performing assets and loan defaults under the SARFAESI Act. The financial results are described as extracts and unaudited, with references to limited review by auditors and approval by the board. The document includes detailed financial data for the quarter and nine months ended December 31, 2025, which is substantive financial information. The presence of quarterly and nine-month financial results with actual figures and notes indicates this is an Interim / Quarterly Report. The demand notice related to loan defaults is a legal/regulatory notice but is part of a broader document primarily focused on financial results. Therefore, the best classification is Interim / Quarterly Report (IR). 9M 2025
2026-02-16 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a statement submitted to the National Stock Exchange of India regarding the use of proceeds from a Preferential Issue for the quarter ended 31st December 2025. It references Regulation 32 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and confirms no deviation or variation in the use of funds raised. The document includes a detailed table showing the allocation and utilization of funds, reviewed by the Audit Committee and Board of Directors. The content is a compliance disclosure related to the use of capital raised, specifically a quarterly statement on deviation or variation in use of proceeds from a preferential issue. This type of filing is a regulatory compliance update rather than a full financial report or earnings release. It fits best under Regulatory Filings (RNS) as it is a regulatory announcement and does not constitute a full financial report or other specific category filings like Capital/Financing Update (CAP) or Interim Report (IR).
2026-02-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.